Pyelonephritis and Myocarditis Therapeutic Pipeline H2 2014 Review Reports

DALLAS, November 20, 2014 /PRNewswire/ --

RnRMarketResearch.com adds Pyelonephritis - Pipeline Review, H2 2014 and Myocarditis - Pipeline Review, H2 2014 market research reports on therapeutic pipelines to the life science industry intelligence collection of its online library.

These reports provide comprehensive information on the therapeutic development for Pyelonephritis and Myocarditis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocarditis and Pyelonephritis and special features on late-stage and discontinued projects.

Complete report on Pyelonephritis - Pipeline Review, H2 2014 is available at http://www.rnrmarketresearch.com/pyelonephritis-pipeline-review-h2-2014-market-report.html and the Myocarditis - Pipeline Review, H2 2014 report is available at http://www.rnrmarketresearch.com/myocarditis-pipeline-review-h2-2014-market-report.html .

These therapeutic pipeline reports on Pyelonephritis and Myocarditis feature investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. An individual report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by an expert team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The reports enhance decision making capabilities and help to create effective counter strategies to gain competitive advantage. They strengthen R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

These reports provide a snapshot of the global therapeutic landscape of Pyelonephritis and Myocarditis. Each report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities. The report reviews key players involved in the therapeutics development for Myocarditis and Pyelonephritis and enlists all their major and minor projects. The report summarizes all the dormant and discontinued pipeline projects. A review of the Pyelonephritis and Myocarditis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages. A detailed assessment of monotherapy and combination therapy pipeline projects is provided. Coverage of the Pyelonephritis and Myocarditis pipeline on the basis of target, MoA, route of administration and molecule type as well as latest news and deals relating related to pipeline products are covered in these reports.

Order a copy of Pyelonephritis - Pipeline Review, H2 2014 at http://www.rnrmarketresearch.com/contacts/purchase?rname=242179 and the Myocarditis - Pipeline Review, H2 2014 report is available for purchase at http://www.rnrmarketresearch.com/contacts/purchase?rname=242189 .

Reasons to buy one or both of these reports: Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies. Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. Develop strategic initiatives by understanding the focus areas of leading companies. Identify and understand important and diverse types of therapeutics under development for Pyelonephritis and Myocarditis. Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline. Devise corrective measures for pipeline projects by understanding Myocarditis and Pyelonephritis pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies like Achaogen Inc., AstraZeneca PLC, Cubist Pharmaceuticals, Inc., Merck & Co., Inc., MerLion Pharmaceuticals Pte Ltd, The Medicines Company, CEL-SCI Corporation and Novartis AG are discussed in these research reports.

Explore more reports on therapeutics industry and pharmaceuticals market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals .

About Us: 

RnRMarketResearch.com is an online database of market research reports and in-depth studies of over 5000 micro markets. Not limited to any one industry, we offer research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Contact:  

Ritesh Tiwari

TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252

Tel:  +1-888-391-5441
sales@rnrmarketresearch.com